Asthma
Conditions
Interventions
None listed
Sponsors
Teikyo University School of Medicine
KAGOSHIMA University(Kagoshima),National Hospital Organization Tokyo National Hospital(Tokyo),Fukushima Medical University Hospital(Fukushima),Showa University(Tokyo),JUNTENDO Uiversity(Tokyo),KINDAI University(Oosaka),KANAZAWA University(Ishikawa),University of TSUKUBA (Ibaraki)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with asthma, followed-up by participating facilities, and treated by inhaled corticosteroids are eligible. Spirometry and FeNO testing is essential.
Exclusion criteria
Exclusion criteria: Patients treated by unapproved drugs for clinical studies. Patients judged as inappropriate for participating to the study by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time course of annual exacerbation frequency stratified by phenotypes of asthma | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Time course of ACT score, pulmonary function, biomarkers (blood eosinophil counts, total IgE, FeNO) stratified by phenotypes of asthma 2. Prognostic factors for exacerbation frequency and annual decline in FEV1 3. Improvement in exacerbation frequency, ACT sore, and pulmonary function after introduction of biologics in patients treated by antibody therapies | — |
Countries
Japan
Contacts
Public ContactHiroyuki Nagase
Teikyo University School of Medicine Division of Respiratory Medicine and Allergology, Department of Medicine
Outcome results
None listed